Literature DB >> 11399661

Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum.

R W Rees1, D J Ralph, M Royle, S Moncada, S Cellek.   

Abstract

We have examined the effect of an inhibitor of Rho-kinase, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate (Y-27632), on the contractions elicited by noradrenergic nerve stimulation and by phenylephrine in the human and rabbit penile corpus cavernosum. In both tissues, after treatment with scopolamine (10 microM) and N(G)-nitro-L-arginine methyl ester (L-NAME; 300 microM), electrical field stimulation (EFS) elicited noradrenergic contractions. These contractions were inhibited by Y-27632 in a concentration-dependent manner. The compound caused concentration-dependent relaxation of phenylephrine-contracted tissues, which were treated with scopolamine (10 microM), guanethidine (10 microM) and L-NAME (300 microM). These results suggest that Rho-kinase is involved in noradrenergic contractile pathway in the cavernosal smooth muscle of the penis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399661      PMCID: PMC1572821          DOI: 10.1038/sj.bjp.0704124

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

Review 1.  Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II.

Authors:  A P Somlyo; A V Somlyo
Journal:  J Physiol       Date:  2000-01-15       Impact factor: 5.182

2.  Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: a comparison with other species.

Authors:  S Cellek; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Evaluation of Y-27632, a rho-kinase inhibitor, as a bronchodilator in guinea pigs.

Authors:  K Iizuka; Y Shimizu; H Tsukagoshi; A Yoshii; T Harada; K Dobashi; T Murozono; T Nakazawa; M Mori
Journal:  Eur J Pharmacol       Date:  2000-10-13       Impact factor: 4.432

4.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.

Authors:  T Ishizaki; M Uehata; I Tamechika; J Keel; K Nonomura; M Maekawa; S Narumiya
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

5.  Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon.

Authors:  S Cellek; J Rodrigo; E Lobos; P Fernández; J Serrano; S Moncada
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 6.  Ca2+ homeostasis in vascular smooth muscle.

Authors:  B Himpens; L Missiaen; R Casteels
Journal:  J Vasc Res       Date:  1995 Jul-Aug       Impact factor: 1.934

7.  Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway.

Authors:  K Chitaley; C J Wingard; R Clinton Webb; H Branam; V S Stopper; R W Lewis; T M Mills
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

8.  Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization.

Authors:  A Yoshii; K Iizuka; K Dobashi; T Horie; T Harada; T Nakazawa; M Mori
Journal:  Am J Respir Cell Mol Biol       Date:  1999-06       Impact factor: 6.914

9.  The effect of chloride removal on the responses of the isolated rat anococcygeus muscle to alpha 1-adrenoceptor stimulation.

Authors:  W A Large
Journal:  J Physiol       Date:  1984-07       Impact factor: 5.182

10.  Nitrergic-noradrenergic interaction in penile erection: a new insight into erectile dysfunction.

Authors:  S Cellek
Journal:  Drugs Today (Barc)       Date:  2000 Feb-Mar       Impact factor: 2.245

View more
  19 in total

1.  The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum.

Authors:  Selim Cellek
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 2.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 3.  Physiology of penile erection and pathophysiology of erectile dysfunction.

Authors:  Robert C Dean; Tom F Lue
Journal:  Urol Clin North Am       Date:  2005-11       Impact factor: 2.241

Review 4.  Cavernous smooth muscles: innovative potential therapies are promising for an unrevealed clinical diagnosis.

Authors:  Ahmed Mohamed Hassanin; Ahmed Zain Abdel-Hamid
Journal:  Int Urol Nephrol       Date:  2019-10-15       Impact factor: 2.370

5.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

6.  Involvement of Rho kinase and protein kinase C in carbachol-induced calcium sensitization in beta-escin skinned rat and guinea-pig bladders.

Authors:  N Tugba Durlu-Kandilci; Alison F Brading
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

7.  Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle.

Authors:  Alexandra Wibberley; Zunxuan Chen; Erding Hu; J Paul Hieble; Timothy D Westfall
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  Bladder outlet obstruction triggers neural plasticity in sensory pathways and contributes to impaired sensitivity in erectile dysfunction.

Authors:  Anna P Malykhina; Qi Lei; Shaohua Chang; Xiao-Qing Pan; Antonio N Villamor; Ariana L Smith; Allen D Seftel
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-27       Impact factor: 3.619

9.  Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens.

Authors:  Kansu Büyükafşar; Adnan Levent; Mustafa Ark
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

10.  Up-regulation of the RhoA/Rho-kinase signaling pathway in corpus cavernosum from endothelial nitric-oxide synthase (NOS), but not neuronal NOS, null mice.

Authors:  Fernanda B M Priviero; Li-Ming Jin; Zhekang Ying; Cleber E Teixeira; R Clinton Webb
Journal:  J Pharmacol Exp Ther       Date:  2010-01-21       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.